Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Blood nets $136mm through upsized public stock sale

Executive Summary

Global Blood Therapeutics Inc. (developing drugs for blood-based diseases including sickle cell disease (SCD) and idiopathic pulmonary fibrosis) netted $136mm through the public offering of 5.9mm common shares (including the overallotment) at $24.50. (The company had originally hoped to bring in $75mm.) Money will go towards pipeline activities, including work on lead candidate GBT440, in Phase I/II for SCD.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies